Based on the above molecular mechanism, we developed a combination treatment comprising the ELFN1-AS1 ASO or EZH2 inhibitor GSK126 and oxaliplatin can significantly reverse the resistance of drug-resistant cells to oxaliplatin, impairing cell survival, and limiting tumor growth in mice. The gene discussed is EZH2; the disease is neoplasm.